Teacher Retirement System of Texas Raises Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Teacher Retirement System of Texas lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,372 shares of the specialty pharmaceutical company's stock after purchasing an additional 2,346 shares during the period. Teacher Retirement System of Texas' holdings in Jazz Pharmaceuticals were worth $2,139,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth $25,000. Jones Financial Companies Lllp boosted its position in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 130 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company's stock valued at $38,000 after acquiring an additional 129 shares during the last quarter. Lindbrook Capital LLC grew its holdings in shares of Jazz Pharmaceuticals by 82.6% in the fourth quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company's stock valued at $48,000 after purchasing an additional 176 shares during the period. Finally, Itau Unibanco Holding S.A. increased its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company's stock worth $49,000 after purchasing an additional 172 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on JAZZ. Needham & Company LLC reiterated a "buy" rating and issued a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, March 5th. UBS Group upgraded shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $145.00 to $179.00 in a report on Friday, March 7th. JPMorgan Chase & Co. increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright upped their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Finally, Royal Bank of Canada dropped their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $187.71.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CMO Robert Iannone sold 2,403 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $138.41, for a total value of $332,599.23. Following the sale, the chief marketing officer now directly owns 79,621 shares of the company's stock, valued at approximately $11,020,342.61. This represents a 2.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 6,500 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,736 shares of company stock worth $4,022,825. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Down 2.8 %

NASDAQ JAZZ traded down $3.48 during trading hours on Friday, hitting $122.92. 1,709,286 shares of the company were exchanged, compared to its average volume of 735,368. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market cap of $7.47 billion, a price-to-earnings ratio of 17.31, a PEG ratio of 1.04 and a beta of 0.44. The company has a 50 day moving average of $132.30 and a two-hundred day moving average of $122.66. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.